HP and cranioectodermal dysplasia: In CeD, ongoing research into immunotherapy, zonulin inhibitors, microbiota modulation, nanotechnologies, monoclonal antibodies, and vaccines promise to improve gluten tolerance, reduce intestinal inflammation, and improve patient outcomes.